Endo Health Solutions Inc (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

39.00USD
10:57am EDT
Price Change (% chg)

$0.54 (+1.40%)
Prev Close
$38.46
Open
$38.52
Day's High
$39.19
Day's Low
$38.52
Volume
88,813
Avg. Vol
527,130
52-wk High
$39.90
52-wk Low
$25.01

ENDP.OQ

Chart for ENDP.OQ

About

Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm , Opana ER, Voltaren Gel, Percocet , Frova , Supprelin LA, Vantas , Valstar and Fortesta Gel.... (more)

Overall

Beta: 0.75
Market Cap (Mil.): $4,316.78
Shares Outstanding (Mil.): 112.24
Dividend: --
Yield (%): --

Financials

  ENDP.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -5.69 -- --
ROI: -11.05 19.48 18.76
ROE: -42.46 20.17 19.59
Search Stocks

DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan

NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.

27 Jun 2013

Endo Health to slash 15 percent jobs, looks to sell some assets

- Endo Health Solutions Inc said it plans to cut about 15 percent of its workforce and explore strategic alternatives for some assets as the company looks to cut costs ahead of generic competition for two of its biggest drugs.

05 Jun 2013

UPDATE 1-Endo Health to slash 15 pct jobs, looks to sell some assets

* Cuts FY adj profit view to $4.10-$4.40/shr from $4.40-$4.70/shr

05 Jun 2013

Endo Health to cut 15 pct jobs, explore options for two units

June 5 - Endo Health Solutions Inc said it plans to cut about 15 percent of its global workforce and will explore strategic alternatives for two units as the company looks to reduce about $325 million in annual operating expenses.

05 Jun 2013

FDA denies approval to Endo's testosterone drug again

- The Food and Drug Administration has for the third time refused approval to Endo Health Solutions Inc's injectable testosterone drug Aveed, pressing for a still better plan to manage the risks associated with the drug.

30 May 2013

FDA allows generic forms of Endo Health's Opana ER painkiller

- The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

10 May 2013

UPDATE 1-FDA allows generic forms of Endo Health's Opana ER painkiller

May 10 - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

10 May 2013

Panel divided over safety of Endo's testosterone drug

- An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

18 Apr 2013

UPDATE 1-US panel divided over safety of Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

18 Apr 2013

U.S. FDA panel deadlocked over Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was deadlocked over whether the agency should approve Endo Health Solutions Inc's experimental drug to treat low testosterone in men.

18 Apr 2013

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $93.89 +0.39
Pfizer Inc. (PFE.N) $29.19 -0.04
Abbott Laboratories (ABT.N) $36.91 +0.28
Teva Pharmaceutical Industries Limited (TEVA.TA) 13,920.00₪ -200.00
Mylan Inc. (MYL.OQ) $33.63 +0.07
Actavis Inc (ACT.N) $135.53 +1.26
Allergan, Inc. (AGN.N) $91.71 +0.59

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks